MEI Pharma (MEIP.US): The 2024 Q3 financial report achieved revenue of $0, with a previous value of US$5.894 million, with an expected value of US$40,000; earnings per share of -1.37 USD, previous value of -2.32 USD, and expected value of -1.52 USD.
MEI Pharma(MEIP.US)：2024年Q3财报实现营收0美元，前值为589.4万美元，预期值为4万美元；每股收益为-1.37美元，前值为-2.32美元，预期值为-1.52美元。
MEI Pharma (MEIP.US): The 2024 Q3 financial report achieved revenue of $0, with a previous value of US$5.894 million, with an expected value of US$40,000; earnings per share of -1.37 USD, previous value of -2.32 USD, and expected value of -1.52 USD.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.